hat
Anastrozole ki te teste pou diminye estwojèn, ki gen ladan estradyol, nan gason. Ekzèsis estradiol nan gason ka lakòz benign pwostatik hyperplasia, gynecomastia, ak sentòm ipoganadism. Li kapab tou kontribye nan ogmante risk pou konjesyon serebral, atak kè, enflamasyon kwonik, elajisman pwostat ak kansè pwostat. Gen kèk atlèt ak bòs mason kò ki sèvi ak anastrozol kòm yon pati nan sik esteroyid yo diminye ak anpeche sentòm estwojèn depase - gynecomastia, emosyonèl ak retansyon dlo. Done etid sijere dòz nan 0.5 mg a 1 mg yon jou diminye serid estradiol pa apeprè 50% nan gason, ki diferan nan fanm postmenopausal.
eng
Anastrozole has been tested for reducing estrogens, including estradiol, in men. Excess estradiol in men can cause benign prostatic hyperplasia, gynecomastia, and symptoms of hypogonadism. It can also contribute to increased risk of stroke, heart attack, chronic inflammation, prostate enlargement and prostate cancer. Some athletes and body builders use anastrozole as part of their steroid cycle to reduce and prevent symptoms of excess estrogen--gynecomastia, emotional lability and water retention. Study data suggest dosages of 0.5 mg to 1 mg a day reduce serum estradiol by approximately 50% in men, which differs in postmenopausal women.